JP2004523582A5 - - Google Patents

Download PDF

Info

Publication number
JP2004523582A5
JP2004523582A5 JP2002573758A JP2002573758A JP2004523582A5 JP 2004523582 A5 JP2004523582 A5 JP 2004523582A5 JP 2002573758 A JP2002573758 A JP 2002573758A JP 2002573758 A JP2002573758 A JP 2002573758A JP 2004523582 A5 JP2004523582 A5 JP 2004523582A5
Authority
JP
Japan
Prior art keywords
alkyl
heteroaryl
pharmaceutically acceptable
aryl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002573758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004523582A (ja
Filing date
Publication date
Priority claimed from SE0100903A external-priority patent/SE0100903D0/xx
Application filed filed Critical
Publication of JP2004523582A publication Critical patent/JP2004523582A/ja
Publication of JP2004523582A5 publication Critical patent/JP2004523582A5/ja
Pending legal-status Critical Current

Links

JP2002573758A 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤 Pending JP2004523582A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100903A SE0100903D0 (sv) 2001-03-15 2001-03-15 Compounds
PCT/SE2002/000474 WO2002074749A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
JP2004523582A JP2004523582A (ja) 2004-08-05
JP2004523582A5 true JP2004523582A5 (enExample) 2006-01-05

Family

ID=20283375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002573761A Pending JP2004527512A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤
JP2002573758A Pending JP2004523582A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002573761A Pending JP2004527512A (ja) 2001-03-15 2002-03-13 メタロプロテイナーゼ阻害剤

Country Status (25)

Country Link
US (2) US20040110809A1 (enExample)
EP (2) EP1370535A1 (enExample)
JP (2) JP2004527512A (enExample)
KR (2) KR20030082988A (enExample)
CN (2) CN1509274A (enExample)
AR (1) AR035444A1 (enExample)
AU (1) AU2002237633B2 (enExample)
BR (2) BR0207985A (enExample)
CA (2) CA2440475A1 (enExample)
CZ (2) CZ20032498A3 (enExample)
EE (2) EE200300450A (enExample)
HU (2) HUP0400193A3 (enExample)
IL (2) IL157650A0 (enExample)
IS (2) IS6945A (enExample)
MX (2) MXPA03008183A (enExample)
MY (1) MY129188A (enExample)
NO (2) NO20034032L (enExample)
NZ (2) NZ528141A (enExample)
PL (2) PL364705A1 (enExample)
RU (2) RU2003127731A (enExample)
SE (1) SE0100903D0 (enExample)
SK (2) SK10912003A3 (enExample)
UA (2) UA74624C2 (enExample)
WO (2) WO2002074749A1 (enExample)
ZA (2) ZA200306733B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
US7005439B2 (en) * 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
ATE445400T1 (de) 2001-05-25 2009-10-15 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix- metalloproteinasen
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202692D0 (sv) * 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
FR2845000B1 (fr) 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
ES2364068T3 (es) * 2004-08-19 2011-08-24 Quest Pharmaceutical Services 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolin-2,4-diona y sus análogos como inhibidores de macrófago elastasa.
JPWO2006051937A1 (ja) * 2004-11-15 2008-05-29 塩野義製薬株式会社 ヘテロ5員環誘導体
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
MX2008014290A (es) 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos monociclicos.
BRPI0710328A2 (pt) 2006-05-08 2011-08-09 Ariad Pharma Inc composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
ES2313841B1 (es) * 2007-06-26 2010-01-12 Proyecto De Biomedicina Cima, S.L. Composiciones para tratamiento anti-fibrinolitico.
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
SG11202011318QA (en) 2018-05-15 2020-12-30 Foresee Pharmaceuticals Usa Inc Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) * 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) * 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc D−α−アミノ酸の製造方法
JPH0597814A (ja) * 1991-10-02 1993-04-20 Ajinomoto Co Inc 5−(ヒドロキシメチル)ヒダントイン誘導体の製法
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
DE69620639T2 (de) * 1995-11-22 2002-10-17 Darwin Discovery Ltd., Cambridge Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
CA2268418A1 (en) * 1996-10-22 1998-04-30 Pharmacia & Upjohn Company .alpha.-amino sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors
IL132170A0 (en) * 1997-05-06 2001-03-19 Novo Nordisk As Novel heterocyclic compounds
ATE210639T1 (de) * 1997-05-09 2001-12-15 Hoechst Ag Substituierte diaminocarbonsäuren
DK1001930T3 (da) * 1997-07-31 2003-03-24 Abbott Lab N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
PL342009A1 (en) * 1998-02-04 2001-05-07 Novartis Ag Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1077974A1 (en) * 1998-05-14 2001-02-28 Du Pont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
WO1999065867A1 (en) * 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
EP1004578B1 (en) * 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
AU1817700A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6340691B1 (en) * 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US20020006920A1 (en) * 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
EP1078923B1 (en) * 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
MXPA02001498A (es) * 1999-08-12 2003-07-21 Pharmacia & Italia S P A Derivados de 3(5)-amino-pirazol, procedimiento para la preparacion de los mismos y usos como agentes antitumorales.
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020065219A1 (en) * 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
MXPA03008180A (es) * 2001-03-15 2003-12-12 Astrazeneca Ab Inhibidores de metaloproteinasa.
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
ATE445400T1 (de) * 2001-05-25 2009-10-15 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix- metalloproteinasen
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Similar Documents

Publication Publication Date Title
RU2003127731A (ru) Ингибиторы металлопротеиназ
JP2004527515A5 (enExample)
RU2388750C2 (ru) Ингибиторы фосфодиэстеразы 4, включая аналоги n-замещенного диариламина
JP2004523581A5 (enExample)
RU2003127734A (ru) Ингибиторы металлопротеиназ
RU99105567A (ru) Производные пропионовой кислоты и их использование
RU2003127732A (ru) Ингибиторы металлопротеиназ
RU2009133259A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
RU2005121667A (ru) 5-замещенные пиразиновые или пиридиновые активаторы глюкокиназы
RU2008106058A (ru) Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона
JP2009507011A5 (enExample)
CA2565813A1 (en) Substituted methyl aryl or heteroaryl amide compounds
CA2131797A1 (en) Condensed indole derivatives as 5ht4-receptor antagonists
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
RU2006107653A (ru) Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли
CA2401502A1 (en) Carboxylic acid derivatives as ip antagonists
RU2011153772A (ru) Фторированные аминотриазольные производные
RU2004130426A (ru) Циклические амиды
RU2005128833A (ru) Замещенные сульфамидами производные ксантина для применения в качестве ингибиторов фосфоенолпируваткарбоксикиназы (рерск)
RU2011104223A (ru) Азотсодержащее ароматическое гетероциклическое соединение
RU99100277A (ru) Производные тиазола
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
RU2000131184A (ru) Соединения, обладающие свойствами, способствующими выделению гормона роста
JP2004525183A5 (enExample)